Clinical Trial

Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation

Study acronym: ZVS203e
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This trial employs a single-arm, open-label seamless Phase I/II design, consisting of two stages: Phase I dose exploration and Phase II dose expansion.The primary objective of this trial is to evaluate the safety, tolerability, and efficacy of subretinal injection of ZVS203e solution.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-28.
Status change: Not Yet Recruiting → Recruiting 2026-06-15
Trial Details
NCT Number NCT06952842
Lead Sponsor Chigenovo Co., Ltd
Conditions Retinitis Pigmentosa
Enrollment 18 participants
Start Date 2025-08-04
Primary Completion 2030-06-18 (estimated)
Study Completion 2045-06-18 (estimated)
Updated on ClinicalTrials.gov 2026-06-17